Chiasma is dedicated to improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently only available as injections. The company is conducting an international Phase 3 clinical trial of octreotide capsules (conditionally trade-named “Mycapssa®”) for the maintenance treatment of adult acromegaly patients to support a potential submission of a Marketing Authorization Application to the European Medicines Agency. Chiasma received a Complete Response Letter from the U.S. Food and Drug Administration on April 15, 2016 regarding its New Drug Application for Mycapssa. Chiasma is headquartered in the United States with a wholly owned subsidiary in Israel. Mycapssa and TPE are trademarks of Chiasma.

Press Releases

Chiasma Names Mark J. Fitzpatrick Chief Executive Officer

Read More

Chiasma Announces Workforce Reduction

Read More

Chiasma Provides Corporate Update and Reports Second Quarter 2016 Results

Read More

Upcoming Events

There are no events available at this time.

IR Contact

Cammy Duong
MacDougall Biomedical Communications
Phone: 781-591-3443